We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+7.75%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.7B
AUM Growth
+$80.1M
Cap. Flow
-$54.5M
Cap. Flow %
-1.47%
Top 10 Hldgs %
34.9%
Holding
147
New
53
Increased
24
Reduced
24
Closed
35

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$134M
2
LLY icon
Eli Lilly
LLY
+$114M
3
HOLX
Hologic
HOLX
+$80.8M
4
NEO icon
NeoGenomics
NEO
+$60.6M
5
BIIB icon
Biogen
BIIB
+$55.7M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$182M
2
ISRG icon
Intuitive Surgical
ISRG
+$103M
3
ABBV icon
AbbVie
ABBV
+$66.8M
4
MDT icon
Medtronic
MDT
+$61.4M
5
BHC icon
Bausch Health
BHC
+$60M

Sector Composition

Rank Sector Weight
1 Healthcare 95.4%
2 Technology 1.61%
3 Financials 0.67%
4 Consumer Discretionary 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
S icon
76
SentinelOne
S
$6.25B
$8.5M 0.23%
+200,000
New +$8.5M
ESPR
77
DELISTED
Esperion Therapeutics
ESPR
$8.46M 0.23%
+400,000
New +$9.63M
ONCS
78
DELISTED
OncoSec Medical Incorporated
ONCS
$7.87M 0.21%
127,273
-30,454
-19% -$2.76M
TIL icon
79
Instil Bio
TIL
$48.2M
$7.73M 0.21%
20,000
– –
VIR icon
80
Vir Biotechnology
VIR
$1.51B
$7.66M 0.21%
+162,000
New +$7.37M
PHVS icon
81
Pharvaris
PHVS
$2.39B
$7.45M 0.2%
400,000
– –
WGS icon
82
GeneDx Holdings
WGS
$1.82B
$7.36M 0.2%
15,909
-758
-5% -$325K
GLUE icon
83
Monte Rosa Therapeutics
GLUE
$1.96B
$6.81M 0.18%
+300,000
New +$6.11M
DNLI icon
84
Denali Therapeutics
DNLI
$3.81B
$6.75M 0.18%
+86,100
New +$5.33M
ATAI icon
85
AtaiBeckley Inc
ATAI
$2.66B
$6.49M 0.18%
+350,987
New +$6.48M
TRML
86
DELISTED
Tourmaline Bio
TRML
$6.41M 0.17%
+43,636
New +$6.68M
ARYD
87
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$5.36M 0.14%
500,000
– –
BLSA
88
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$5.26M 0.14%
500,000
– –
MSAC
89
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$5.02M 0.14%
+520,000
New +$5.08M
FIGS icon
90
FIGS
FIGS
$1.66B
$5.01M 0.14%
+100,000
New +$3.74M
PANA
91
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$5.01M 0.14%
+500,000
New +$5.01M
SNTI icon
92
Senti Biosciences Holdings
SNTI
$11.7M
$4.97M 0.13%
+50,000
New +$4.99M
HCAQ
93
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
$4.92M 0.13%
500,000
– –
CELC icon
94
Celcuity
CELC
$4.06B
$4.8M 0.13%
+200,000
New +$5.15M
CFLT
95
DELISTED
Confluent
CFLT
$4.75M 0.13%
+100,000
New +$4.84M
CMIIU
96
DELISTED
CM Life Sciences II Inc. Unit
CMIIU
$4.44M 0.12%
330,000
-6,700
-2% -$89.2K
WKME
97
DELISTED
WalkMe Ltd. Ordinary Shares
WKME
$4.39M 0.12%
+150,000
New +$4.45M
MLTX icon
98
MoonLake Immunotherapeutics
MLTX
$1.66B
$4.14M 0.11%
400,000
– –
OBIO icon
99
Orchestra BioMed
OBIO
$228M
$4.08M 0.11%
400,000
– –
SNCE
100
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$4M 0.11%
20,000
– –
2 3
4
5 6

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q2 2021 Portfolio in Review

As of Q2 2021, Avidity Partners Management held 147 positions worth $3.7B, up 2.2% from $3.62B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Avidity Partners Management's Q2 2021 filing shows 53 new, 24 increased, 24 reduced and 35 closed positions. Its largest new stake was Eli Lilly: 565,500 shares worth $130M. The largest sale was AstraZeneca, an estimated $182M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology and Financials.

  • Avidity Partners Management's largest Q2 2021 buy was Eli Lilly: 565,500 shares worth $130M.
  • Avidity Partners Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $134M increase.
  • Avidity Partners Management's biggest Q2 2021 reduction was AbbVie, cutting an estimated $66.8M.
  • Avidity Partners Management fully exited AstraZeneca in Q2 2021, selling an estimated $182M.
  • Avidity Partners Management's ten largest holdings make up 35% of its $3.7B portfolio in Q2 2021.
  • Avidity Partners Management opened 53 new positions and closed 35 in Q2 2021.
  • Avidity Partners Management's portfolio value rose 2.2% quarter-over-quarter to $3.7B.

Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.